Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis

Nicoletta Meucci, Eduarde Nobile-Orazio, Guglielmo Scarlato

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Seven consecutive patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous immunoglobulins (IVIg; 0.4 g/kg per day for 5 consecutive days followed by monthly 2-day infusions at the same daily dosage) continued with oral cyclophosphamide (1-2 mg/kg per day), for 4-13 months (mean 8.1). Response to treatment was assessed by means of the Medical Research Council (MRC) rating scale for muscle strength on 40 muscles (10 per limb), a clinical scale for bulbar function and a modified Rankin disability scale. All patients continued to deteriorate during treatment on as regards both their MRC score and either their bulbar or Rankin score or both. The progression of the disease during treatment, expressed as the monthly variation in MRC score (mean = - 2.71; SD = 1.36), was no slower than that estimated before therapy (mean = 1.81; SD = 0.93). Even if the results of this small, uncontrolled study do not permit the exclusion of an effect of IVIg on the progression of ALS, they also do not provide any evidence that this expensive form of therapy consistently slows the course of the disease.

Original languageEnglish
Pages (from-to)117-120
Number of pages4
JournalJournal of Neurology
Volume243
Issue number2
DOIs
Publication statusPublished - 1996

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Amyotrophic Lateral Sclerosis
Biomedical Research
Therapeutics
Muscle Strength
Cyclophosphamide
Disease Progression
Extremities
Muscles

Keywords

  • Amyotrophic lateral sclerosis
  • Intravenous immunoglobulins
  • Motor neuron disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. / Meucci, Nicoletta; Nobile-Orazio, Eduarde; Scarlato, Guglielmo.

In: Journal of Neurology, Vol. 243, No. 2, 1996, p. 117-120.

Research output: Contribution to journalArticle

Meucci, Nicoletta ; Nobile-Orazio, Eduarde ; Scarlato, Guglielmo. / Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. In: Journal of Neurology. 1996 ; Vol. 243, No. 2. pp. 117-120.
@article{65c7d346566d48809ad1a8a76a6b202a,
title = "Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis",
abstract = "Seven consecutive patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous immunoglobulins (IVIg; 0.4 g/kg per day for 5 consecutive days followed by monthly 2-day infusions at the same daily dosage) continued with oral cyclophosphamide (1-2 mg/kg per day), for 4-13 months (mean 8.1). Response to treatment was assessed by means of the Medical Research Council (MRC) rating scale for muscle strength on 40 muscles (10 per limb), a clinical scale for bulbar function and a modified Rankin disability scale. All patients continued to deteriorate during treatment on as regards both their MRC score and either their bulbar or Rankin score or both. The progression of the disease during treatment, expressed as the monthly variation in MRC score (mean = - 2.71; SD = 1.36), was no slower than that estimated before therapy (mean = 1.81; SD = 0.93). Even if the results of this small, uncontrolled study do not permit the exclusion of an effect of IVIg on the progression of ALS, they also do not provide any evidence that this expensive form of therapy consistently slows the course of the disease.",
keywords = "Amyotrophic lateral sclerosis, Intravenous immunoglobulins, Motor neuron disease",
author = "Nicoletta Meucci and Eduarde Nobile-Orazio and Guglielmo Scarlato",
year = "1996",
doi = "10.1007/BF02444000",
language = "English",
volume = "243",
pages = "117--120",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "2",

}

TY - JOUR

T1 - Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis

AU - Meucci, Nicoletta

AU - Nobile-Orazio, Eduarde

AU - Scarlato, Guglielmo

PY - 1996

Y1 - 1996

N2 - Seven consecutive patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous immunoglobulins (IVIg; 0.4 g/kg per day for 5 consecutive days followed by monthly 2-day infusions at the same daily dosage) continued with oral cyclophosphamide (1-2 mg/kg per day), for 4-13 months (mean 8.1). Response to treatment was assessed by means of the Medical Research Council (MRC) rating scale for muscle strength on 40 muscles (10 per limb), a clinical scale for bulbar function and a modified Rankin disability scale. All patients continued to deteriorate during treatment on as regards both their MRC score and either their bulbar or Rankin score or both. The progression of the disease during treatment, expressed as the monthly variation in MRC score (mean = - 2.71; SD = 1.36), was no slower than that estimated before therapy (mean = 1.81; SD = 0.93). Even if the results of this small, uncontrolled study do not permit the exclusion of an effect of IVIg on the progression of ALS, they also do not provide any evidence that this expensive form of therapy consistently slows the course of the disease.

AB - Seven consecutive patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous immunoglobulins (IVIg; 0.4 g/kg per day for 5 consecutive days followed by monthly 2-day infusions at the same daily dosage) continued with oral cyclophosphamide (1-2 mg/kg per day), for 4-13 months (mean 8.1). Response to treatment was assessed by means of the Medical Research Council (MRC) rating scale for muscle strength on 40 muscles (10 per limb), a clinical scale for bulbar function and a modified Rankin disability scale. All patients continued to deteriorate during treatment on as regards both their MRC score and either their bulbar or Rankin score or both. The progression of the disease during treatment, expressed as the monthly variation in MRC score (mean = - 2.71; SD = 1.36), was no slower than that estimated before therapy (mean = 1.81; SD = 0.93). Even if the results of this small, uncontrolled study do not permit the exclusion of an effect of IVIg on the progression of ALS, they also do not provide any evidence that this expensive form of therapy consistently slows the course of the disease.

KW - Amyotrophic lateral sclerosis

KW - Intravenous immunoglobulins

KW - Motor neuron disease

UR - http://www.scopus.com/inward/record.url?scp=0030042956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030042956&partnerID=8YFLogxK

U2 - 10.1007/BF02444000

DO - 10.1007/BF02444000

M3 - Article

C2 - 8750546

AN - SCOPUS:0030042956

VL - 243

SP - 117

EP - 120

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 2

ER -